---
title: "Hemogenyx Cleared to Advance CAR-T Therapy Trial After Positive Safety Review"
publisher: "Share Talk"
author: "sharetalk"
published: "2025-10-29T08:12:08+00:00"
modified: "2025-10-29T08:12:49+00:00"
date: 2025-10-29
canonical: "https://www.share-talk.com/hemogenyx-cleared-to-advance-car-t-therapy-trial-after-positive-safety-review/"
category: "Health"
categories: ["Health", "Healthcare", "Pharmaceutical"]
tags: ["biopharmaceutica", "COVID-19", "Dr Vladislav Sandler", "Global Pharma", "gold rush", "H.C. Wainwright", "HEMO", "Hemogenyx", "Hemogenyx Pharma", "Pharma", "Share Talk", "Vladislav Sandler"]
image: "https://i0.wp.com/www.share-talk.com/wp-content/uploads/2025/10/N4P-8TH-JAN-23.webp?fit=750%2C406&ssl=1"
format: "news"
language: "en-GB"
---

# Hemogenyx Cleared to Advance CAR-T Therapy Trial After Positive Safety Review

**Published:** October 29, 2025
**Author:** sharetalk
**Categories:** Health, Healthcare, Pharmaceutical
**Tags:** biopharmaceutica, COVID-19, Dr Vladislav Sandler, Global Pharma, gold rush, H.C. Wainwright, HEMO, Hemogenyx, Hemogenyx Pharma, Pharma, Share Talk, Vladislav Sandler
**Featured image:** ![](https://i0.wp.com/www.share-talk.com/wp-content/uploads/2025/10/N4P-8TH-JAN-23.webp?fit=750%2C406&ssl=1)

---

[Hemogenyx Pharmaceuticals (LON: HEMO)](https://www.investegate.co.uk/announcement/rns/hemogenyx-pharmaceuticals--hemo/clinical-trial-update-and-grant-of-share-awards/9200443) has received clearance from its **independent Data Safety Monitoring Board (DSMB)** to **proceed to the next adult dose level** in its **Phase I clinical trial of HG-CT-1**, the company’s proprietary **CAR-T therapy** targeting **relapsed or refractory acute myeloid leukaemia (AML)**.

The decision follows a **successful safety review** of the first three adult patients, with **no dose-limiting toxicities** observed. The DSMB’s approval also allows **pediatric patient recruitment** to begin at the **initial dose level**.

The ongoing **dose-escalation study** is designed to evaluate **safety, tolerability, and preliminary efficacy** of HG-CT-1 across both adult and pediatric cohorts — marking a **key de-risking milestone** and potential **value inflexion point** as higher-dose testing commences.

To acknowledge the contribution of its scientific team, **Hemogenyx granted 6,000 Restricted Share Units (RSUs)** to key staff members.

CEO **Dr. Vladislav Sandler** said the DSMB’s clearance “**validates HG-CT-1’s safety profile and demonstrates continued progress toward delivering this potentially life-saving therapy to patients in need**.”

---

**Original URL:** https://www.share-talk.com/hemogenyx-cleared-to-advance-car-t-therapy-trial-after-positive-safety-review/
*Created by [WP Markdown Endpoint](https://wpmarkdownendpoint.com/)*